Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chan

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Palliative Medicine|December 16, 2025
A 10-year service evaluation of a multidisciplinary neuro-palliative care model in motor neuron disease: Impact on palliative care service delivery & advance care planningWai Kei Vicky Chung, Ka Po Chan, Dany Young Hsu, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitorsAaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Immunohorizons|July 30, 2019
Generation of IL-3-Secreting CD4<sup>+</sup> T Cells by Microbial Challenge at Skin and Mucosal BarriersShajo Kunnath-Velayudhan, Michael F Goldberg, Neeraj K Saini, et al.
JCO Precision Oncology|April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR StudyEugene R Ahn, Michael Rothe, Pam K Mangat, et al.
Plos Pathogens|July 29, 2017
Mycobacterium tuberculosis universal stress protein Rv2623 interacts with the putative ATP binding cassette (ABC) transporter Rv1747 to regulate mycobacterial growthLisa N Glass, Ganduri Swapna, Sivagami Sundaram Chavadi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2016
CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfectionTaylor W Foreman, Smriti Mehra, Denae N LoBato, et al.
Nature Communications|November 3, 2025
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22Elisia Villemure, Tom Januario, Mingshuo Zeng, et al.
Gynecologic Oncology|June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004Xiaodan Tang, Helen Huang, John D Peipert, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Palliative Medicine|December 16, 2025
A 10-year service evaluation of a multidisciplinary neuro-palliative care model in motor neuron disease: Impact on palliative care service delivery & advance care planningWai Kei Vicky Chung, Ka Po Chan, Dany Young Hsu, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitorsAaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Immunohorizons|July 30, 2019
Generation of IL-3-Secreting CD4<sup>+</sup> T Cells by Microbial Challenge at Skin and Mucosal BarriersShajo Kunnath-Velayudhan, Michael F Goldberg, Neeraj K Saini, et al.
JCO Precision Oncology|April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR StudyEugene R Ahn, Michael Rothe, Pam K Mangat, et al.
Plos Pathogens|July 29, 2017
Mycobacterium tuberculosis universal stress protein Rv2623 interacts with the putative ATP binding cassette (ABC) transporter Rv1747 to regulate mycobacterial growthLisa N Glass, Ganduri Swapna, Sivagami Sundaram Chavadi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2016
CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfectionTaylor W Foreman, Smriti Mehra, Denae N LoBato, et al.
Nature Communications|November 3, 2025
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22Elisia Villemure, Tom Januario, Mingshuo Zeng, et al.
Gynecologic Oncology|June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004Xiaodan Tang, Helen Huang, John D Peipert, et al.
Pageof 16